Full-year 2025 revenue reached $344.2 million, a 4% increase over $332.1 million in 2024. Excluding DecisionDx-SCC and IDgenetix revenue, growth was 34%. Fourth quarter 2025 revenue was $87.0 million, a 1% increase over $86.3 million in the same period of 2024. Excluding DecisionDx-SCC and IDgenetix, revenue growth was 43%. Total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 37% for the full year 2025 over 2024. DecisionDx-Melanoma test reports delivered in 2025 were 39,083, up from 36,008 in 2024. TissueCypher Barretts Esophagus test reports delivered in 2025 were 39,014, an 86% increase from 20,956 in 2024. The company reported a net loss of $24.2 million for 2025, compared to a net income of $18.2 million in 2024. Adjusted EBITDA for 2025 was $44.0 million, a decrease from $75.0 million in 2024. Cash, cash equivalents, and marketable investment securities totaled $299.5 million as of December 31, 2025. The limited access launch of AdvanceAD-Tx materially expanded the total addressable market.